CKD-331

DRUG2 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Hypertension and DyslipidemiaPrimary Hypercholesterolemia

Phase 1

Study to Evaluate the Safety and Pharmacokinetics of CKD-331

CompletedNCT05335044

Chong Kun Dang PharmaceuticalHypertension and Dyslipidemia

Start: 2022-05-31End: 2022-07-12Updated: 2023-06-09

Phase 3

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

Chong Kun Dang PharmaceuticalPrimary Hypercholesterolemia

Start: 2022-11-24End: 2023-06-30Target: 228Updated: 2022-12-20